US Stock Insider Trading | Royalty Pharma disclosed one insider transaction on February 2nd

K-LinePoet · 2026-02-04T11:39:50+00:00

Royalty Pharma executive Urist Marshall sold 20,000 shares on January 30, 2026, and has recently engaged in multiple equity transactions. The company, founded in 2020, is a major buyer of biopharmaceutical royalties and is dedicated to funding industry innovation.

K-LinePoet

2026-02-04 11:39:50

Abstract generation in progress

On February 2, 2026, Royalty Pharma (RPRX) disclosed an insider trading transaction. Executive Urist Marshall sold 20,000 shares on January 30, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Urist Marshall	January 30, 2026	Sell	20,000	41.09	821,800
January 26, 2026	Executive	Urist Marshall	January 23, 2026	Sell	20,000	40.26	805,100
January 23, 2026	Executive	Coyne Terrance P.	January 20, 2026	Sell	69,600	39.35	2,737,900
January 20, 2026	Executive	Urist Marshall	January 16, 2026	Sell	20,000	39.52	790,300
January 13, 2026	Executive	Urist Marshall	January 9, 2026	Sell	20,000	40.78	815,600
January 6, 2026	Executive	Urist Marshall	January 2, 2026	Sell	20,000	38.48	769,700
January 6, 2026	Executive	Coyne Terrance P.	January 2, 2026	Sell	69,600	38.42	2,673,000
January 2, 2026	Director	Bassler Bonnie L	December 31, 2025	Buy	967	38.74	37,500
December 29, 2025	Executive	Urist Marshall	December 26, 2025	Sell	20,000	39.32	786,400
December 22, 2025	Executive	Urist Marshall	December 19, 2025	Sell	20,000	38.38	767,600

【Company Information】

Royalty Pharma plc was incorporated on February 6, 2020, under the laws of England and Wales. The company is the largest buyer of biopharmaceutical royalties and a major funder of innovation in the biopharmaceutical industry. Since its founding in 1996, the company has been a pioneer in the royalty rights market, collaborating with innovators from academic institutions, research hospitals, and non-profit organizations (ranging from small and medium biotech firms to leading global pharmaceutical companies). The company has accumulated a portfolio of royalties that entitle them to payments based on topline sales of many industry-leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri, and Xtandi. The company funds innovation in the biopharmaceutical industry directly or indirectly, when they partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and when they acquire existing royalties from original innovators, thereby indirectly supporting innovation in the industry.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.